Matthew J Elrick1, Eliza Gordon-Lipkin2, Thomas O Crawford1, Keith Van Haren3, Kevin Messacar4, Nicole Thornton5, Elizabeth Dee5, Annie Voskertchian6, Jessica R Nance1, Laura S Muñoz1, Mark P Gorman7, Leslie A Benson7, David L Thomas8, Carlos A Pardo1, Aaron M Milstone5,6, Priya Duggal5. 1. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Kennedy Krieger Institute, Baltimore, Maryland. 3. Department of Neurology and Neurological Sciences, Stanford University, Stanford, California. 4. Department of Pediatrics, Children's Hospital Colorado, the University of Colorado, Aurora. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 6. Division of Infectious Disease, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland. 7. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts. 8. Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
Importance: Acute flaccid myelitis (AFM) is an emerging poliolike illness of children whose clinical spectrum and associated pathogens are only partially described. The case definition is intentionally encompassing for epidemiologic surveillance to capture all potential AFM cases. Defining a restrictive, homogenous subpopulation may aid our understanding of this emerging disease. Objective: To evaluate the extent to which the US Centers for Disease Control and Prevention (CDC) case definition of AFM incorporates possible alternative diagnoses and to assess the plausibility of a case definition that enriches the biological homogeneity of AFM for inclusion in research studies. Design, Setting, and Participants: Retrospective case analysis of children younger than 18 years diagnosed as having AFM between 2012 and 2016 using the CDC case definition. Group 1 included patients recruited from the United States and Canada based on the CDC case definition of AFM. Group 2 included patients referred to the Johns Hopkins Transverse Myelitis Center for evaluation of suspected AFM. Patients' records and imaging data were critically reviewed by 3 neurologists to identify those cases with definable alternative diagnoses, and the remaining patients were categorized as having restrictively defined AFM (rAFM). Clinical characteristics were compared between patients with rAFM (cases) and those with alternative diagnoses, and a case description distinguishing these AFM groups was identified. Interrater reliability of this description was confirmed for a subset of cases by a fourth neurologist. Data were analyzed between May 2017 and November 2018. Main Outcomes and Measures: Proportion of patients with possible alternative diagnosis. Results: Of the 45 patients who met the CDC AFM case definition and were included, the mean age was 6.1 years; 27 were boys (60%); and 37 were white (82%), 3 were Asian (7%), 1 was Hispanic (2%), and 4 were mixed race/ethnicity (9%). Of the included patients, 34 were classified as having rAFM, and 11 had alternate diagnoses (including transverse myelitis, other demyelinating syndromes, spinal cord stroke, Guillain-Barre syndrome, Chiari I myelopathy, and meningitis). Factors differing between groups were primarily asymmetry of weakness, lower motor neuron signs, preceding viral syndrome, symptoms evolving over hours to days, absence of sensory deficits, and magnetic resonance imaging findings. A case description was able to reliably define the rAFM group. Conclusions and Relevance: We present an approach for defining a homogeneous research population that may more accurately reflect the pathogenesis of the prototypical poliomyelitis-like subgroup of AFM. The definition of rAFM forms a blueprint for inclusion criteria in future research efforts, but more work is required for refinement and external validation.
Importance: Acute flaccid myelitis (AFM) is an emerging poliolike illness of children whose clinical spectrum and associated pathogens are only partially described. The case definition is intentionally encompassing for epidemiologic surveillance to capture all potential AFM cases. Defining a restrictive, homogenous subpopulation may aid our understanding of this emerging disease. Objective: To evaluate the extent to which the US Centers for Disease Control and Prevention (CDC) case definition of AFM incorporates possible alternative diagnoses and to assess the plausibility of a case definition that enriches the biological homogeneity of AFM for inclusion in research studies. Design, Setting, and Participants: Retrospective case analysis of children younger than 18 years diagnosed as having AFM between 2012 and 2016 using the CDC case definition. Group 1 included patients recruited from the United States and Canada based on the CDC case definition of AFM. Group 2 included patients referred to the Johns Hopkins Transverse Myelitis Center for evaluation of suspected AFM. Patients' records and imaging data were critically reviewed by 3 neurologists to identify those cases with definable alternative diagnoses, and the remaining patients were categorized as having restrictively defined AFM (rAFM). Clinical characteristics were compared between patients with rAFM (cases) and those with alternative diagnoses, and a case description distinguishing these AFM groups was identified. Interrater reliability of this description was confirmed for a subset of cases by a fourth neurologist. Data were analyzed between May 2017 and November 2018. Main Outcomes and Measures: Proportion of patients with possible alternative diagnosis. Results: Of the 45 patients who met the CDC AFM case definition and were included, the mean age was 6.1 years; 27 were boys (60%); and 37 were white (82%), 3 were Asian (7%), 1 was Hispanic (2%), and 4 were mixed race/ethnicity (9%). Of the included patients, 34 were classified as having rAFM, and 11 had alternate diagnoses (including transverse myelitis, other demyelinating syndromes, spinal cord stroke, Guillain-Barre syndrome, Chiari I myelopathy, and meningitis). Factors differing between groups were primarily asymmetry of weakness, lower motor neuron signs, preceding viral syndrome, symptoms evolving over hours to days, absence of sensory deficits, and magnetic resonance imaging findings. A case description was able to reliably define the rAFM group. Conclusions and Relevance: We present an approach for defining a homogeneous research population that may more accurately reflect the pathogenesis of the prototypical poliomyelitis-like subgroup of AFM. The definition of rAFM forms a blueprint for inclusion criteria in future research efforts, but more work is required for refinement and external validation.
Authors: Alexander L Greninger; Samia N Naccache; Kevin Messacar; Anna Clayton; Guixia Yu; Sneha Somasekar; Scot Federman; Doug Stryke; Christopher Anderson; Shigeo Yagi; Sharon Messenger; Debra Wadford; Dongxiang Xia; James P Watt; Keith Van Haren; Samuel R Dominguez; Carol Glaser; Grace Aldrovandi; Charles Y Chiu Journal: Lancet Infect Dis Date: 2015-03-31 Impact factor: 25.071
Authors: Keith Van Haren; Patrick Ayscue; Emmanuelle Waubant; Anna Clayton; Heather Sheriff; Shigeo Yagi; Rose Glenn-Finer; Tasha Padilla; Jonathan B Strober; Grace Aldrovandi; Debra A Wadford; Charles Y Chiu; Dongxiang Xia; Kathleen Harriman; James P Watt; Carol A Glaser Journal: JAMA Date: 2015 Dec 22-29 Impact factor: 56.272
Authors: Kevin Messacar; Teri L Schreiner; Keith Van Haren; Michele Yang; Carol A Glaser; Kenneth L Tyler; Samuel R Dominguez Journal: Ann Neurol Date: 2016-08-04 Impact factor: 10.422
Authors: James J Sejvar; Adriana S Lopez; Margaret M Cortese; Eyal Leshem; Daniel M Pastula; Lisa Miller; Carol Glaser; Anita Kambhampati; Kayoko Shioda; Negar Aliabadi; Marc Fischer; Nicole Gregoricus; Robert Lanciotti; W Allan Nix; Senthilkumar K Sakthivel; D Scott Schmid; Jane F Seward; Suxiang Tong; M Steven Oberste; Mark Pallansch; Daniel Feikin Journal: Clin Infect Dis Date: 2016-06-17 Impact factor: 9.079
Authors: Patrick Ayscue; Keith Van Haren; Heather Sheriff; Emmanuelle Waubant; Paul Waldron; Shigeo Yagi; Cynthia Yen; Anna Clayton; Tasha Padilla; Chao Pan; John Reichel; Kathleen Harriman; James Watt; James Sejvar; William Allan Nix; Daniel Feikin; Carol Glaser Journal: MMWR Morb Mortal Wkly Rep Date: 2014-10-10 Impact factor: 17.586
Authors: Olwen C Murphy; Kevin Messacar; Leslie Benson; Riley Bove; Jessica L Carpenter; Thomas Crawford; Janet Dean; Roberta DeBiasi; Jay Desai; Matthew J Elrick; Raquel Farias-Moeller; Grace Y Gombolay; Benjamin Greenberg; Matthew Harmelink; Sue Hong; Sarah E Hopkins; Joyce Oleszek; Catherine Otten; Cristina L Sadowsky; Teri L Schreiner; Kiran T Thakur; Keith Van Haren; Carolina M Carballo; Pin Fee Chong; Amary Fall; Vykuntaraju K Gowda; Jelte Helfferich; Ryutaro Kira; Ming Lim; Eduardo L Lopez; Elizabeth M Wells; E Ann Yeh; Carlos A Pardo Journal: Lancet Date: 2020-12-23 Impact factor: 79.321
Authors: Jelte Helfferich; Marjolein Knoester; Coretta C Van Leer-Buter; Rinze F Neuteboom; Linda C Meiners; Hubert G Niesters; Oebele F Brouwer Journal: Eur J Pediatr Date: 2019-07-23 Impact factor: 3.183
Authors: Liz J Walker; Bruce R Thorley; Anne Morris; Elizabeth J Elliott; Nathan Saul; Philip N Britton Journal: Emerg Infect Dis Date: 2022-01 Impact factor: 6.883
Authors: Giulia Fadda; Cesar A Alves; Julia O'Mahony; Denise A Castro; E Ann Yeh; Ruth Ann Marrie; Douglas L Arnold; Patrick Waters; Amit Bar-Or; Arastoo Vossough; Brenda Banwell Journal: JAMA Netw Open Date: 2021-10-01
Authors: Sarah Kidd; Adriana S Lopez; Jennifer L Konopka-Anstadt; W Allan Nix; Janell A Routh; M Steven Oberste Journal: Emerg Infect Dis Date: 2020-08-24 Impact factor: 6.883